Edition:
United Kingdom

Immune Pharmaceuticals Inc (IMNP.OQ)

IMNP.OQ on NASDAQ Stock Exchange Capital Market

0.77USD
8:59pm GMT
Change (% chg)

$-0.05 (-5.49%)
Prev Close
$0.82
Open
$0.83
Day's High
$0.83
Day's Low
$0.77
Volume
58,520
Avg. Vol
157,463
52-wk High
$5.02
52-wk Low
$0.76

Summary

Name Age Since Current Position

Elliot Maza

61 2017 President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Director

Anthony Fiorino

2017 Chief Operating Officer, Chief Medical Officer

John Clark

2017 Controller

Cameron Durrant

54 2015 Lead Independent Director

Daniel Teper

55 2017 Director

John Neczesny

2016 Independent Director

Jeffrey Paley

47 2016 Independent Director

Anna Baran

Director of Investor Relations and Corporate Communications

Biographies

Name Description

Elliot Maza

Mr. Elliot M. Maza, J.D, CPA is President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Director of Immune Pharmaceuticals Inc. He became a director of the Company on January 14, 2015. From November 2014 to January 2015, Mr. Maza served as a consultant to the Company. Mr. Maza has been the Chairman of the Board of Directors, Chief Executive Officer and Chief Financial Officer of Intellect Neurosciences, Inc., a biotechnology company focused on the development of therapeutics neurodegenerative diseases, since July 2014. From May 2006 to June 2014, Mr. Maza served in several management positions at Intellect Neurosciences, Inc., including, Executive Vice President from May 2006 to March 2007, President from March 2007 to October 2011, Chief Financial Officer from May 2006 to the present and member of the Board of Directors since June 2007. Mr. Maza served as Chief Executive Officer, Chief Financial Officer and member of the Board of Directors of Biozone Pharmaceuticals, Inc., a contract manufacturer of prescription and over-the-counter (OTC) drug products and anti-aging and skin care products, from July 2011 until January 2014. From December 2003 to May 2006, Mr. Maza served as Chief Financial Officer of Emisphere Technologies, Inc., a biopharmaceutical company specializing in oral drug delivery. From March 1999 to December 2003, Mr. Maza was a partner at Ernst and Young, LLP. During the period from May 1989 to March 1999, Mr. Maza served as an Associate and subsequently Vice President in the Fixed Income divisions of Goldman Sachs, Inc. and JP Morgan Securities, Inc. Mr. Maza practiced law at Sullivan and Cromwell in New York from September 1985 to April 1989. We believe that Mr. Maza is qualified to serve as the Interim Chief Executive Officer and director of the Company based on his experience as a senior executive in several biotech and biopharma companies.

Anthony Fiorino

Dr. Anthony Fiorino, M.D. Ph.D., is Chief Operating Officer, Chief Medical Officer of the Company. Dr. Fiorino brings to the Company a unique background and specialized expertise, which includes extensive experience in medical affairs, drug development and biotechnology finance and operations. He joins the Company from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as President and Chief Executive Officer. Prior to joining Triumvira, Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics (NASDAQ:BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the NASDAQ. Prior to joining BrainStorm, he was the Founder, President and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.

John Clark

Cameron Durrant

Dr. Cameron Durrant, M.D., is Lead Independent Director of Company. He was an Independent Director of the Company. Dr. Durrant is an accomplished biotech entrepreneur, marketer, financier, and a business and corporate development professional with a strong medical base as an MD. He has served as board chairman and director and operated as CEO or interim CEO, as well as CFO, for both private and public companies. Most recently, Dr. Durrant served as a corporate officer of Hi-Tech Pharmacal (recently sold to Akorn) and CEO of the ECR division (subsequently divested by Akorn to Valeant). He has been a senior executive at Johnson and Johnson as Worldwide Vice President, and previously as Vice President Pharmacia Corporation (until its acquisition by Pfizer). Dr. Durrant started his career at Merck and then at GSK. He has served as the founding investor, Chairman, CEO and CFO of publicly-traded PediatRx, Executive Chairman of publicly-traded Anavex, CEO of PediaMed Pharmaceuticals, a founding director of Bexion Pharmaceuticals, a board member of Topaz Pharmaceuticals (acquired by sanofi-aventis), a board member of Alcyone Life Sciences and ReliefBand Technologies. Dr. Durrant has been an advisor to Microsoft Corporation, Prism Pharmaceuticals (acquired by Baxter), Pilgrim Software (acquired by a private equity group), Aprecia Pharmaceuticals and Saxa Private Equity Partners. He has also been involved in creating companies around targeted early-stage technologies with Cincinnati Children's Hospital and assisted numerous private equity groups in their diligence efforts. Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, and his DipCH from the Melbourne Academy, Australia and his Master of Business Administration from Henley Management College, Oxford, UK.

Daniel Teper

Dr. Daniel G. Teper, Pharm.D., is Director of Immune Pharmaceuticals Inc. He had been appointed as Chairman of the Board, Chief Executive Officer from August 25, 2013 to December 15, 2014. Dr. Teper was the founder, Chairman and Chief Executive Officer of Immune Ltd. from January 2010 through the Merger. From 2005 to 2009, Dr. Teper was a New York-based Managing Partner and Head of North America at Bionest Partners. From 2000 until 2004, Dr Teper held various senior management roles in the United States including Senior Vice President of Sales and Business Development at Softwatch, an internet healthcare company, where he assisted in raising $30 million in venture capital and expanding the company to over 150 employees. Dr. Teper started his career in 1984 at the Novartis headquarters in Basel, Switzerland and then in the United States from 1985 until 1990 where he held management responsibilities in sales and marketing and eventually became the Head of New Product Development for Cardiovascular Products. From 1990 until 1992, Dr. Teper held general management positions in France, first as a Senior Vice President and Head of Marketing & Sales of Laboratories at GlaxoSmithKline, and then as President and Chief Operating Officer of Laboratories at Delagrange (which was acquired by Synthelabo, a predecessor to Sanofi). In 1993, Dr. Teper founded and was the CEO of WINTEC Pharma, a specialty pharmaceutical company. In 1995, Dr. Teper sold the anti-infectives segment of WINTEC Pharma to Norgine (UK) and the dermatology segment to Galephar (Belgium). In 1999, Dr. Teper co-founded Novagali (NYSE Euronext: NOVA), a pharmaceutical company specializing in ophthalmology and which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD, where he was a J. Salmon Scholar.

John Neczesny

Mr. John Neczesny is Director of the Company. Mr. Neczesny will be a member both of the Audit Committee and of the Compensation Committee. Mr. Neczesny brings over 27 years of investment banking and corporate experience to this role. Mr. Neczesny has been a Managing Director at Oberon Securities, LLC, a boutique investment bank, since 2012, where he advises on and executes M&A and financing transactions principally for healthcare companies. Previously, he was Vice President, Corporate Development at Par Pharmaceutical Companies from 2009 to 2011. From 1998 to 2008, Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in the Healthcare group, where he rose to Managing Director and was involved in numerous M&A and capital markets transactions for pharmaceutical, biotechnology and medical technology companies. Mr. Neczesny earned an MBA in Finance from New York University Stern School of Business and a Bachelor of Science degree in Chemistry from the University of Delaware.

Jeffrey Paley

Dr. Jeffrey Paley is Independent Director of the company. He brings over 19 years of experience in the healthcare industry to his new role. Dr. Paley has been an active clinician and consultant for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Dr. Paley has also consulted for several biotechnology and specialty pharmaceutical companies, most notably in the areas of clinical development and business development and he has engineered transactions worth over$600 million. Dr. Paley founded Access Medical Associates in 2003, after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders. He has served as a Director of Kellbenx and Retrophin and currently serves as a Director of Kalytera, Avenue Therapeutics and Remote Radiology Inc. Dr. Paley trained at Harvard Medical Schooland completed a residency in Internal Medicine at Massachusetts General Hospital.

Anna Baran

Basic Compensation